



Twist Bioscience Launches Alpha Manufacturing Program For Synthetic Genes

April 23, 2015

— Platform Delivers High-Quality Genes Using 10,000-well Silicon-Based Proprietary Platform —

— Amyris to Become Early Adopter of Technology Platform —

— CEO Emily LeProust, Ph.D., to Keynote SynBioBeta London Conference —

SAN FRANCISCO, April 22nd, 2015 — Twist Bioscience, a company focused on synthetic DNA, today announced the launch of an alpha manufacturing program for synthetic genes produced using its proprietary silicon-based DNA synthesis platform. During the alpha manufacturing program, Twist will work with customers to optimize the efficiency of its first synthetic gene product offering.

One of the first companies to participate in the alpha manufacturing program is Amyris, the industrial bioscience company.

"Twist technology has the potential to disrupt the current process of creating synthetic genes, helping Amyris further increase the efficiency in our current automated strain engineering pipeline and our ability to rapidly deliver new molecules to market. We are looking forward to working with Twist, building on promising early results, to further test and validate their novel platform for DNA synthesis," said Darren Platt, vice president of data science at Amyris.

"Delivery of our initial products marks a significant milestone for the organization," said Emily LeProust Ph.D., chief executive officer of Twist Bioscience. "Using our initial capacity to validate our product offering will enable Twist to rapidly accelerate future product deliveries toward longer genes, increasingly rapid turnaround time and unrivaled synthetic gene price points."

Dr. LeProust will provide the keynote presentation at SynBioBeta London, where she will provide an overview of the Twist technology and product roadmap. The presentation will be held on April 22, 2015 at 2:30 p.m. GMT in the Great Hall, Sherfield Building, Imperial College, London, UK.

About Twist Bioscience

Twist has developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, the Twist DNA synthesis platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at <https://twitter.com/TwistBioscience>.

Contacts

Twist Bioscience Contacts:

Investor Contact

Maeve Conneighton | Argot Partners

T [212-600-1902](tel:212-600-1902) | E maeve@argotpartners.com

Media Contact

Angela Bitting | Twist Bioscience

T [925-202-6211](tel:925-202-6211) | E media@twistbioscience.com